A Clinical Study of Rozanolixizumab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

My CIDP CHOICE Clinical Study

Clinical research studies are scientific evaluations in people, led by researchers and physicians. They can help advance the understanding of a disease and are the most important way for researchers to find out if potential new treatments are safe and effective. Studies like these are needed to be able to make new treatments available to patients.

The international My CIDP CHOICE study is currently enrolling CIDP patients to help us understand how effective and safe a new investigational drug, called rozanolixizumab, is for the treatment of CIDP. Rozanolixizumab is a non-blood product and aims at lowering the levels of immunoglobulins (IgG) in the body, including IgG that are thought to be linked to CIDP.

At the beginning of the My CIDP CHOICE study, the study participant’s Ig treatment will be replaced by the study treatment (either rozanolixizumab or placebo). It will be given as a subcutaneous (under the skin) infusion. Study participants will have an equal chance of being assigned to rozanolixizumab or placebo. A placebo looks exactly like the investigational drug, but it contains no medicinally active ingredients. In case the study treatment does not work for the study participant, Ig treatment will immediately be prescribed again (without waiting for the end of the study).

About the Study

The study is looking to enroll a total of approximately 34 participants at approximately 24 study sites globally. The My CIDP CHOICE study will last for about 28 weeks (up to a maximum of 40 weeks) for every participant. Some study visits may be conducted at home. Participants for whom the study treatment works well may be able to enroll in a 6-month follow-up study where everyone receives rozanolixizumab (no placebo), provided they meet the entry criteria.

Patients interested in joining the My CIDP CHOICE study must:

- Be 18 years of age or older
- Have a definite or probable diagnosis of CIDP
- Have prior experience of discontinuing/reducing their immunoglobulin treatment
- Have been receiving immunoglobulin treatment with a stable dose for at least 4 months

You can find more information on clinicaltrials.gov if you search for the identifier NCT03861481 or CIDP01 in the “Other terms” field.

CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV

If you are interested in participating, you can contact UCBCares, who can refer you to a study physician in your area.

UCB Cares - +1-844-599-CARE (2273) - UCBCares@ucb.com